Abstract:449 Background: Sarcomatoid differentiation (SD) in renal cell carcinoma (RCC) is associated with poor survival and heightened response to immune checkpoint blockade. Detection of SD can be challenging due to spatial heterogeneity and sampling error. Herein, we introduce a novel tissue–informed epigenomic approach to noninvasively identify sarcomatoid differentiation in patients with RCC from cell-free DNA (cfDNA) using <1mL of plasma. Methods: Methylated immunoprecipitation and high-throughput sequencing (MeDIP-seq) was performed on pathologically reviewed clear cell RCC frozen tissue samples with and without SD (sarcomatoid-RCC and epithelioid-RCC, resp.) collected at the Dana-Farber Cancer Institute. Differentially methylated regions (DMRs) between sarcomatoid and epithelioid subtypes were identified using DESeq2 (false discovery rate of q < 0.01). Then, MeDIP-seq was performed on cell-free DNA (cfMeDIP-seq) from patients with sarc-RCC and epi-RCC. A Sarcomatoid Methylation Score (SMS) was derived for each sample by aggregating the methylated cfDNA signal at tissue-derived sarcomatoid-enriched DMRs (sarc-DMRs), while normalizing to signal at epithelioid-enriched DMRs (epi-DMRs). Scores were compared between the two groups using a Wilcoxon rank-sum test. A classifier was built to distinguish sarc-RCC from epi-RCC based on SMS and its performance was evaluated using the area under the receiver operating characteristic (AUROC) curve. Results: We identified 32,086 DMRs between 9 sarc-RCC and 10 epi-RCC tissue samples at a false discovery rate of q < 0.01, among which We selected 16,083 DMRs that are enriched in sarcomatoid vs. epithelioid. We generated high-quality cfMeDIP-seq profiles from plasma of 46 patients, 13 with sarc-RCC and 33 with epi-RCC. SMS were significantly higher in sarc-RCC vs. epi-RCC plasma samples (p = 6.7×10 -8 ). These scores achieved an AUROC curve of 0.95 for classifying patients with sarc-RCC from patients with epi-RCC. Conclusions: We present the first proof of concept study for the detection of sarcomatoid differentiation in RCC based on tissue-informed assessment of DNA methylation signals in cfDNA using <1mL of plasma. This approach could overcome the challenges of spatial heterogeneity and sampling error that make identification of sarc-RCC difficult. More generally, it establishes a paradigm for identifying histologic subtypes of cancer based on their epigenomic correlates from cfDNA, with possible therapeutic implications in real-time.

Sarcoma diagnosis by DNA methylation classifier: A systematic review, current status and future prospects

A 3-DNA Methylation Signature As a Novel Prognostic Biomarker in Patients with Sarcoma by Bioinformatics Analysis

Sarcoma classification by DNA methylation profiling

A Novel DNA Methylation Signature As an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer

Identification of Methylation Signatures and Rules for Sarcoma Subtypes by Machine Learning Methods.

Can DNA Methylation Profiling Classify Histologic Subtypes and Grades in Soft Tissue Sarcoma?

Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Decoding the DNA methylome of central nervous system tumors: An emerging modality for integrated diagnosis

DNA Methylation Profiling of Salivary Gland Tumors Supports and Expands Conventional Classification

DNA methylation-based classification of central nervous system tumours

The Impact of Next Generation Sequencing on Sarcoma Diagnosis.

Unclassifiable CNS tumors in DNA methylation-based classification: clinical challenges and prognostic impact

Sarcomas: Immune biomarker expression and checkpoint inhibitor trials

Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation.

DNA methylation-based epigenetic signatures predict somatic genomic alterations in gliomas

The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care

Cytogenetics and the biologic basis of sarcomas

Diagnostic classification based on DNA methylation profiles using sequential machine learning approaches.

Role of DNA methylation in cancer development and its clinical applications

Potential Application of Genomic Profiling for the Diagnosis and Treatment of Patients with Sarcoma.